{"entity":{"id":"paper-nct06612151-n-engl-j-med-2026","kind":"paper","name":"Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy","aka":[],"tldr":"Published report from the TAISHAN-302 trial registered as NCT06612151, in New England Journal of Medicine (2026), chosen as the most cited paper whose own text cites the registry id.","summary":"Background: Tambotatug pelitecan (known as Tam-Peli, a new antibody-drug conjugate that targets the immune-checkpoint molecule B7-H3) showed promising clinical efficacy in patients with relapsed extensive-stage small-cell lung cancer in early-phase trials.\n\nMethods: In this phase 3, multicenter, open-label, randomized trial, we assigned eligible patients with small-cell lung cancer that had progressed after first-line platinum-based therapy in a 1:1 ratio to receive tambotatug pelitecan or topotecan. The primary end point was overall survival. The key secondary end points were progression-free survival and objective response as assessed by investigators. Here, we report the results from the prespecified interim analysis.\n\nResults: A total of 451 patients underwent randomization: 225 were assigned to receive tambotatug pelitecan and 226 to receive topotecan. Overall survival was significantly longer with tambotatug pelitecan than with topotecan - a median of 13.3 months (95% confidence interval [CI], 12.1 to could not be estimated), as compared with 9.4 months (95% CI, 7.7 to 10.5); the stratified hazard ratio for death was 0.46 (95% CI, 0.35 to 0.62; P<0.001). Treatment with tambotatug pelitecan also resulted in significantly longer progression-free survival than treatment with topotecan (median, 7.4 months [95% CI, 6.1 to 7.6] vs. 2.8 months [95% CI, 1.8 to 3.0]; stratified hazard ratio, 0.29 [95% CI, 0.23 to 0.37]; P<0.001). A confirmed objective response occurred in 59.1% of the patients in the tambotatug pelitecan group, as compared with 9.7% of those in the topotecan group (P<0.001). The overall incidence of adverse events of grade 3 or higher was lower with tambotatug pelitecan than with topotecan (55.4% vs. 77.9%).\n\nConclusions: Among patients with relapsed small-cell lung cancer after platinum-based therapy, treatment with tambotatug pelitecan resulted in longer overall survival, longer progression-free survival, and a higher percentage of patients with an objective response than treatment with topotecan, with a lower incidence of adverse events of grade 3 or higher. (Funded by the Innovative Drug Research and Development National Science and Technology Major Project and MediLink Therapeutics; TAISHAN-302 ClinicalTrials.gov number, NCT06612151.).\n\nIndexed on Europe PMC as PubMed record 42734213 (DOI 10.1056/nejmoa2610229). Its abstract cites the registry id NCT06612151, which is how it was matched to this trial; no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"N Engl J Med 2026","url":"https://doi.org/10.1056/nejmoa2610229"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/42734213/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/42734213"},{"label":"ClinicalTrials.gov NCT06612151","url":"https://clinicaltrials.gov/study/NCT06612151"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06612151"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2026,"doi":"10.1056/nejmoa2610229","pmid":"42734213","authors":"Zhao Y, Liu H, Meng X, et al.","paperType":"rct","findings":[],"whatItMeans":"This is the paper Europe PMC returns for registry id NCT06612151 with the most citations, so it is the natural first reading for anyone following the TAISHAN-302 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.","caveats":["Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-nct06612151-n-engl-j-med-2026/","neighbours":{"trial":[{"id":"nct06612151","kind":"trial","name":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）","route":"/trials/nct06612151/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}